行情

CRIS

CRIS

居里
NASDAQ

实时行情|Nasdaq Last Sale

1.700
+0.050
+3.03%
休市 16:00 01/24 EST
开盘
1.680
昨收
1.650
最高
1.700
最低
1.610
成交量
17.80万
成交额
--
52周最高
2.900
52周最低
0.9900
市值
5,644.49万
市盈率(TTM)
-1.9125
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CRIS 新闻

  • Curis® and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies
  • PR Newswire.01/13 13:00
  • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • PR Newswire.01/08 21:31
  • Curis up 9% premarket on deal with ImmuNext in cancer
  • seekingalpha.01/07 18:59
  • Curis to in-license cancer candidates from ImmuNext; shares up 9% premarket
  • Seeking Alpha - Article.01/07 13:59

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

CRIS 简况

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
展开

Webull提供Curis, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。